Huaheng Biology (688639): Q2 performance is under pressure, waiting for new products to be released
Huaheng Biology (688639): Short-term performance is under pressure, medium- to long-term growth is clear
Huaheng Biotech (688639): Short-term profit pressure in a single quarter, focus on the pace of new product implementation
Huaheng Biology (688639): Successful construction of bio-methionine is expected to become the company's next growth point
Huaheng Biotech (688639): Performance increased year-on-year, new products are being released soon
Huaheng Biotech (688639): Net profit to mother in '23 +40.32% YoY, 24Q1 net profit to mother +6.62% YoY
Huaheng Biology (688639): 23 years of high performance, new product layout, gradual improvement of synthetic biology platform
Huaheng Biotech (688639): Net profit to mother in '23 +40.32% YoY, 24Q1 net profit to mother +6.62% YoY
Huaheng Biotech (688639): Performance increased year-on-year, and new construction projects continued to be put into operation
Huaheng Biotech (688639) Annual Report and '24 Quarterly Report Review: Net profit increased 40% year-on-year in '23, and major new products are expected to launch in '24
Minsheng Securities released a research report on April 23 stating that Huaheng Biotech (688639.SH) was given a recommended rating. The main reasons for the rating include: 1) falling valine prices dragged down performance, and volume compensation continu
Huaheng Biotech (688639): Valine price reduction drags down Q1 performance, new product release opens up room for growth
Huaheng Biology (688639): Single products are becoming more prominent due to low economic risks and high growth attributes
Huaheng Biology (688639): Projects under construction have increased, and many new products are about to be released
Huaheng Biology (688639): High annual performance growth in '23, optimistic about the company's long-term development space
Huaheng Biotech (688639): Three major projects completed and the product matrix continues to be rich
Huaheng Biotech (688639): Low price of valine in 24Q1 results in short-term pressure, high quality promotion of new project construction and future growth
Guoxin Securities released a research report on April 22 stating that Huaheng Biotech (688639.SH) was given a purchase rating. The main reasons for the rating include: 1) net profit reached a record high in 2023, and the company's business performance was
Huaheng Biotech (688639): 1Q24 profit fell month-on-month, waiting for new products to be released
Huaheng Biology (688639): The product matrix is gradually being enriched and large product volumes can be expected
No Data
No Data